Treatment of autoimmune conditions with Copolymer 1 and related Copolymers
US7425332B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Sep 27, 2006 |
| Grant date | Sep 16, 2008 |
| Priority date | — |
| Expiry date | Sep 27, 2026 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/81
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.